Peter Verdult
Stock Analyst at Exane BNP Paribas
(4.12)
# 1,596
Out of 5,055 analysts
137
Total ratings
61.1%
Success rate
8.4%
Average return
Main Sectors:
Stocks Rated by Peter Verdult
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNY Sanofi | Downgraded: Hold | $50 | $39.77 | +25.72% | 3 | Apr 20, 2026 | |
| RHHBY Roche Holding AG | Downgraded: Hold | $50 | $55.69 | -10.22% | 1 | Mar 17, 2026 | |
| NVO Novo Nordisk | Upgraded: Hold | $61 → $54 | $38.12 | n/a | 4 | Aug 13, 2025 | |
| SWX: GALD Galderma Group AG | Initiated Coverage: Buy | CHF 100.00 | CHF 171.85 | n/a | 1 | Apr 16, 2025 | |
| SWX: NOVN Novartis AG | Initiated Coverage: Buy | CHF 97.00 → CHF 95.00 | CHF 122.66 | n/a | 3 | Apr 16, 2025 | |
| SWX: ROP Roche Holding AG | Initiated Coverage: Buy | CHF 335.00 → CHF 300.00 | CHF 370.90 | n/a | 4 | Apr 16, 2025 | |
| ETR: MRK Merck KGaA | Initiated Coverage: Sell | €190.00 → €107.00 | €141.90 | n/a | 10 | Apr 16, 2025 | |
| EPA: IPN Ipsen S.A. | Initiated Coverage: Hold | €100.00 | €145.60 | n/a | 1 | Apr 16, 2025 | |
| EPA: SAN Sanofi | Initiated Coverage: Buy | €130.00 → €115.00 | €71.82 | n/a | 9 | Apr 16, 2025 | |
| LON: AZN AstraZeneca PLC | Initiated Coverage: Buy | 14,000p → 11,500p | 12,300p | n/a | 7 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | 1,900p → 1,350p | 1,816p | n/a | 7 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $35 | $47.87 | n/a | 1 | Apr 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $116 | $146.88 | n/a | 1 | Apr 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $55 | $59.28 | n/a | 1 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $1,060 → $1,250 | $1,208.74 | n/a | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $130 | $147.37 | n/a | 1 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $58.99 | n/a | 1 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | €33.00 → €29.00 | €45.07 | n/a | 17 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | 2,630p → 2,845p | 1,602p | n/a | 20 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Sell | CHF 1.30 | CHF 4.24 | n/a | 6 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | €35.00 → €30.00 | €26.04 | n/a | 4 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $32 → $26 | $7.24 | n/a | 4 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €23.00 | €9.81 | n/a | 15 | Jan 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | 295p | 344p | n/a | 2 | Sep 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | €21.00 → €31.60 | €2.61 | n/a | 5 | Jun 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $1.43 | n/a | 2 | Jun 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $36.89 | n/a | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $29.40 | n/a | 1 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | CHF 680.00 | CHF 585.40 | n/a | 1 | Jul 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $12.54 | n/a | 1 | Mar 20, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $42.03 | n/a | 1 | Mar 19, 2019 |
Sanofi
Apr 20, 2026
Downgraded: Hold
Price Target: $50
Current: $39.77
Upside: +25.72%
Roche Holding AG
Mar 17, 2026
Downgraded: Hold
Price Target: $50
Current: $55.69
Upside: -10.22%
Novo Nordisk
Aug 13, 2025
Upgraded: Hold
Price Target: $61 → $54
Current: $38.12
Upside: n/a
Galderma Group AG
Apr 16, 2025
Initiated Coverage: Buy
Price Target: CHF 100.00
Current: CHF 171.85
Upside: n/a
Novartis AG
Apr 16, 2025
Initiated Coverage: Buy
Price Target: CHF 97.00 → CHF 95.00
Current: CHF 122.66
Upside: n/a
Roche Holding AG
Apr 16, 2025
Initiated Coverage: Buy
Price Target: CHF 335.00 → CHF 300.00
Current: CHF 370.90
Upside: n/a
Merck KGaA
Apr 16, 2025
Initiated Coverage: Sell
Price Target: €190.00 → €107.00
Current: €141.90
Upside: n/a
Ipsen S.A.
Apr 16, 2025
Initiated Coverage: Hold
Price Target: €100.00
Current: €145.60
Upside: n/a
Sanofi
Apr 16, 2025
Initiated Coverage: Buy
Price Target: €130.00 → €115.00
Current: €71.82
Upside: n/a
AstraZeneca PLC
Apr 16, 2025
Initiated Coverage: Buy
Price Target: 14,000p → 11,500p
Current: 12,300p
Upside: n/a
Apr 16, 2025
Initiated Coverage: Hold
Price Target: 1,900p → 1,350p
Current: 1,816p
Upside: n/a
Apr 15, 2025
Initiated Coverage: Hold
Price Target: $35
Current: $47.87
Upside: n/a
Apr 15, 2025
Initiated Coverage: Buy
Price Target: $116
Current: $146.88
Upside: n/a
Oct 25, 2024
Downgraded: Hold
Price Target: $55
Current: $59.28
Upside: n/a
Oct 25, 2024
Reiterated: Buy
Price Target: $1,060 → $1,250
Current: $1,208.74
Upside: n/a
Oct 25, 2024
Reiterated: Buy
Price Target: $130
Current: $147.37
Upside: n/a
Oct 25, 2024
Reiterated: Buy
Price Target: $40
Current: $58.99
Upside: n/a
Oct 17, 2024
Reiterated: Hold
Price Target: €33.00 → €29.00
Current: €45.07
Upside: n/a
Aug 9, 2024
Rated: Buy
Price Target: 2,630p → 2,845p
Current: 1,602p
Upside: n/a
Jun 21, 2024
Rated: Sell
Price Target: CHF 1.30
Current: CHF 4.24
Upside: n/a
Apr 17, 2024
Reiterated: Hold
Price Target: €35.00 → €30.00
Current: €26.04
Upside: n/a
Mar 1, 2024
Reiterated: Buy
Price Target: $32 → $26
Current: $7.24
Upside: n/a
Jan 10, 2024
Reiterated: Buy
Price Target: €23.00
Current: €9.81
Upside: n/a
Sep 27, 2023
Reiterated: Hold
Price Target: 295p
Current: 344p
Upside: n/a
Jun 8, 2023
Upgraded: Buy
Price Target: €21.00 → €31.60
Current: €2.61
Upside: n/a
Jun 8, 2023
Upgraded: Buy
Price Target: n/a
Current: $1.43
Upside: n/a
Dec 20, 2022
Downgraded: Hold
Price Target: n/a
Current: $36.89
Upside: n/a
Jan 27, 2022
Upgraded: Buy
Price Target: n/a
Current: $29.40
Upside: n/a
Jul 28, 2021
Reiterated: Hold
Price Target: CHF 680.00
Current: CHF 585.40
Upside: n/a
Mar 20, 2019
Reiterated: Buy
Price Target: n/a
Current: $12.54
Upside: n/a
Mar 19, 2019
Upgraded: Buy
Price Target: n/a
Current: $42.03
Upside: n/a